Get the Daily Brief
Latest Biotech News
AI Model PDGrapher Identifies Treatments to Reverse Disease States in Cells
Researchers at Harvard Medical School released PDGrapher, an AI model designed to predict therapeutic targets that can reverse diseased cell gene expression to a healthy state. Unlike traditional...
Small Cell Lung Cancer Forms Functional Synapses with Neurons, Promoting Growth
Groundbreaking research from Stanford Medicine and collaborators revealed that small cell lung cancer (SCLC) cells can form active synaptic connections with neurons in the brain microenvironment....
Novel Non-Neutralizing Antibody Cocktail Provides Broad Flu Protection in Mice
Scientists at Jackson Laboratory developed a cocktail of non-neutralizing antibodies targeting the conserved M2e protein of influenza A virus, demonstrating protection against nearly all tested...
Merck Ends UK R&D Efforts, Cancels London Lab Amid Industry Discontent
Merck has decided to halt all research operations in the UK and abandon its planned $1.3 billion London research center, citing insufficient governmental support for life sciences investment and...
ABCA7 Gene Variants Alter Neuronal Mitochondrial Function Linked to Alzheimer’s
New studies implicate loss-of-function mutations in the ABCA7 gene, a key lipid transporter, in disrupting mitochondrial health in neurons. These alterations contribute to Alzheimer’s disease...
AI Adoption in Healthcare: Industry Faces Challenges in NHS Integration
A University College London study reveals substantial difficulties in procuring and deploying artificial intelligence technologies within the National Health Service (NHS). Stakeholders encounter...
Cancer Immunotherapy Candidate STF-1623 Shows Promise Targeting Innate Immune Checkpoint
Researchers at Stanford University and the Arc Institute developed STF-1623, an ENPP1 inhibitor with ultralong tumor residence time aimed at blocking cancer cells' evasion of innate immune...
Novartis Buys Tourmaline for $1.4 Billion Heart Drug Play
Novartis has agreed to acquire Tourmaline Bio for approximately $1.4 billion, securing the rights to pacibekitug, a Phase 3-ready antibody targeting inflammation in atherosclerotic cardiovascular...
Johnson & Johnson Wins FDA Nod for Bladder Cancer Drug-Device Combo
Johnson & Johnson received FDA approval for Inlexzo, a drug-device combination delivering gemcitabine intravesically to treat Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive...
LB Pharmaceuticals Raises $285 Million in Biotech IPO for Schizophrenia Drug
LB Pharmaceuticals debuted on Nasdaq with a $285 million IPO, the largest biotech offering since February 2025. The company is advancing LB-102, an oral drug candidate for schizophrenia derived...
Eli Lilly Opens AI Platform TuneLab to Biotechs for Drug Discovery Collaboration
Eli Lilly launched TuneLab, an AI platform granting early-stage biotech companies access to Lilly’s drug discovery models trained on decades of data. Participating biotechs contribute their own...
AI Model PDGrapher Identifies Treatments That Reverse Disease States
Harvard Medical School researchers developed PDGrapher, an AI-driven neural network that identifies gene targets capable of reversing diseased cellular states. Unlike traditional single-target...
Small Cell Lung Cancer Exploits Neuronal Synapses to Enhance Growth
Researchers uncovered that small cell lung cancer (SCLC) cells form functional synaptic connections with neurons both in the lung and brain metastases, integrating electrophysiologically into...
Novel Non-neutralizing Antibody Cocktail Shows Broad Flu Protection in Mice
Scientists at Jackson Laboratory developed a cocktail of non-neutralizing antibodies targeting overlapped epitopes of influenza A matrix protein, providing broad protection against diverse...
Breakthrough Single-Cell Atlas Illuminates Human Atherosclerosis Complexity
Researchers unveiled the first integrated single-cell atlas of human atherosclerotic plaques, revealing cellular heterogeneity and molecular pathways underpinning this leading cause of...
J&J’s Inlexzo Gains FDA Approval, Offering New Bladder Cancer Treatment Option
The FDA approved Johnson & Johnson’s Inlexzo, an intravesical gemcitabine-releasing device for patients with BCG-unresponsive, non-muscle invasive bladder cancer. The device delivers chemotherapy...
Novartis Acquires Tourmaline Bio for Cardiovascular Inflammation Drug
Novartis finalized a $1.4 billion acquisition of Tourmaline Bio, gaining its lead asset pacibekitug, an anti-IL-6 monoclonal antibody for treating atherosclerotic cardiovascular disease (ASCVD)....
J&J’s Inlexzo Approved for Non-Muscle Invasive Bladder Cancer
The FDA granted approval for Johnson & Johnson’s Inlexzo, an intravesical device releasing gemcitabine for patients with Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder...
Breakthrough AI Model Identifies Treatments to Reverse Disease States
Researchers at Harvard Medical School unveiled PDGrapher, a novel artificial intelligence model that simultaneously identifies therapeutic targets most likely to reverse diseased cellular states...
Merck Ends UK Research Operations Over Policy Frustrations
Merck halted all discovery research operations in the United Kingdom and canceled plans for a £1 billion London drug research center, citing the government’s insufficient life sciences investments...